Related Experiment Video
Updated: Jul 19, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.7K
Direct Oral Anticoagulants: Navigating Through Clinical Challenges
Maria Ioannou1, Elena Leonidou2, Ioanna Chaziri3
1Department of Cardiology, General Hospital Limassol, State Health Organization Services, 4131, Limassol, Cyprus. mar.ioannou25@gmail.com.
Cardiovascular Drugs and Therapy
|August 8, 2023
Summary
Direct oral anticoagulants (DOACs) offer cardiovascular benefits but require careful selection for patients with comorbidities. This review guides clinicians in optimizing DOAC use for complex cases.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Direct oral anticoagulants (DOACs) have been available for over ten years for cardiovascular conditions.
- Extensive research has generated complex data, leading to challenges in selecting optimal DOACs for patients with multiple comorbidities.
Purpose of the Study:
- To provide a comprehensive review for clinicians on optimizing the use of DOACs.
- To address the dichotomy in selecting appropriate DOAC agents, dosages, and treatment durations for special populations.
Main Methods:
- A thorough literature search and review was conducted, focusing on the last decade.
- Key databases included PubMed, Science Direct Scopus, and Google Scholar.
- The review prioritized current guidelines and recent publications.
Main Results:
- DOACs are established treatments for various cardiovascular conditions.
- Clinical practice faces challenges in DOAC selection for patients with comorbidities.
- Guidance is needed for optimizing DOAC therapy in complex patient profiles.
Conclusions:
- This review aims to guide healthcare professionals in making informed decisions regarding DOACs.
- Further research is necessary to confirm DOAC superiority in cases with clinical uncertainty.
- Optimizing DOAC utilization is crucial for effective patient management.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
01:30Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
01:27Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9